Rodriguez et al. used Safe-Seq to detect mutations in patients with unusual mammography findings before they underwent tissue biopsy and revealed that ctDNA could be employed for early BC diagnosis, finding four mutations (three in TP53 and one in PIK3CA) only in plasma samples, showing that liquid biopsies could capture the tumor heterogeneity [167]. This evidence concerns the gene PIK3CA and breast cancer.